ChrysCapital Acquires 70.68% Stake in Novartis India for ₹1,446 Crore
ChrysCapital has acquired a controlling 70.68% stake in Novartis India Limited (NIL) for ₹1,446 crore, marking its first majority-controlled investment in the Indian pharmaceutical sector. The acquisition brings a longstanding pharmaceutical business under dedicated private equity ownership, with the ambition to build a leading branded-generics platform for the Indian market.